EGFR and lung carcinoma: Likewise, resistance to anti‐EGFR therapies in mCRC with KRAS MAFs < 1% (Azuara et al., 2016; Laurent‐Puig et al., 2015) and longer benefit with tyrosine kinase inhibitor therapy were associated with higher MAFs in EGFR‐mutated lung cancer patients (Ono et al., 2014; Zhou et al., 2011).